EP Wealth Advisors LLC Makes New Investment in ICU Medical, Inc. (NASDAQ:ICUI)

EP Wealth Advisors LLC purchased a new stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 1,354 shares of the medical instruments supplier’s stock, valued at approximately $247,000.

Several other hedge funds and other institutional investors have also made changes to their positions in ICUI. State Street Corp increased its position in ICU Medical by 9.3% in the 3rd quarter. State Street Corp now owns 907,607 shares of the medical instruments supplier’s stock valued at $165,384,000 after acquiring an additional 77,506 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of ICU Medical by 21.7% during the second quarter. Dimensional Fund Advisors LP now owns 311,542 shares of the medical instruments supplier’s stock valued at $36,996,000 after purchasing an additional 55,588 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in ICU Medical by 10.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 301,107 shares of the medical instruments supplier’s stock worth $54,868,000 after purchasing an additional 27,927 shares during the period. WCM Investment Management LLC grew its position in ICU Medical by 1.3% in the 3rd quarter. WCM Investment Management LLC now owns 259,481 shares of the medical instruments supplier’s stock valued at $45,272,000 after buying an additional 3,407 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in ICU Medical by 11.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 216,509 shares of the medical instruments supplier’s stock valued at $25,710,000 after buying an additional 22,310 shares during the period. 96.10% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at ICU Medical

In other news, Director David C. Greenberg sold 972 shares of ICU Medical stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $158.11, for a total value of $153,682.92. Following the transaction, the director now directly owns 5,037 shares of the company’s stock, valued at $796,400.07. This trade represents a 16.18 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the sale, the chief executive officer now owns 104,593 shares in the company, valued at $18,665,666.78. This represents a 10.29 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 40,364 shares of company stock valued at $6,869,878 over the last three months. Company insiders own 6.70% of the company’s stock.

ICU Medical Price Performance

NASDAQ ICUI opened at $161.64 on Friday. The stock has a market capitalization of $3.96 billion, a P/E ratio of -35.37 and a beta of 0.62. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. The business’s fifty day moving average is $171.12 and its two-hundred day moving average is $150.98. ICU Medical, Inc. has a 1 year low of $86.80 and a 1 year high of $196.26.

Wall Street Analysts Forecast Growth

ICUI has been the subject of a number of research analyst reports. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, November 20th. KeyCorp upped their target price on ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 13th. Raymond James lifted their price target on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research report on Thursday, September 12th. Jefferies Financial Group upgraded ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price objective for the company in a report on Wednesday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, ICU Medical has an average rating of “Moderate Buy” and a consensus price target of $177.25.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.